Zdrowie i gospodarka · 12/08/2026
Government Owned Invention Available for License: Monoclonal Antibody (RO4) That Reacts With the Juxta-Membrane Region of Mesothelin
The National Cancer Institute is seeking research co-development partners and/or licensees for a novel monoclonal antibody, RO4, which targets mesothelin-expressing cancers and could be used to treat these types of cancers.